Form 4: Singular Genomics Systems CEO Andrew Spaventa Reports Stock Transactions
SEC Form 4 Filing
CEO Andrew Spaventa of Singular Genomics Systems, Inc. reports stock transactions including the vesting of restricted stock units, sales to cover tax obligations, and gifts to a living trust.
Summary
- Andrew Spaventa, CEO of Singular Genomics Systems, Inc., reported several transactions involving the company's common stock.
- On February 12, 2025, 1,907 shares were issued to Spaventa upon the vesting of restricted stock units (RSUs).
- On February 14, 2025, 800 shares were sold at an average price of $19.89 to cover tax withholding obligations related to the RSU vesting.
- Also on February 14, 2025, 1,107 shares were gifted to The Andrew K. Spaventa Living Trust.
- Spaventa also indirectly owns 142,900 shares through The Andrew K. Spaventa Living Trust and 85 shares through Axon Holdings, LLC.
- The RSUs vest in 16 equal quarterly installments over four years, starting from February 12, 2024.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment about the company's performance.
Industry Context
This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their trading activities. It doesn't necessarily reflect the company's overall performance or future prospects but offers insights into management's perspective on the company's stock.
Comparison to Industry Standards
- Form 4 filings are standard practice for publicly traded companies and their insiders.
- The transactions reported are typical for executives receiving stock-based compensation and managing their personal finances.
- Similar filings can be observed for executives at comparable companies in the genomics and biotechnology sectors, such as Illumina, Pacific Biosciences, and Oxford Nanopore Technologies.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the small volume of shares involved.
- The sale of shares to cover tax obligations is a common practice and unlikely to significantly affect the stock price.
Key Dates
| Date | Description |
|---|---|
| April 9, 2014 | Date of The Andrew K. Spaventa Living Trust |
| February 12, 2024 | Start date for RSU vesting schedule |
| February 12, 2025 | Vesting of 1,907 shares of common stock from RSUs |
| February 14, 2025 | Sale of 800 shares and gift of 1,107 shares to The Andrew K. Spaventa Living Trust |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.